Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more
The Technology Transfer Process for Swissmedic Compliance
EXECUTIVE SUMMARY
Programmatic Asset
CELL & GENE | RNA | BIOLOGICS
Successful technology transfer of AAV-based Advanced Therapy Medicinal Products (ATMPs) for Swissmedic review requires a meticulously documented and scientifically robust protocol. This process encompasses two parallel workstreams: the transfer of the physical manufacturing process (upstream and downstream) and the transfer of the analytical methods required to characterize the vector. A failure in either stream compromises the integrity of the regulatory submission. Key considerations include phase-appropriate analytical qualification, management of quality attributes (CQAs), and ensuring the receiving manufacturing site can replicate production with equivalent purity, potency, and consistency.
Proven Intelligence in AAV Technology Transfer for Swissmedic Submissions
Frequently Asked Questions
What are the primary components of a technology transfer package for an AAV-based ATMP intended for Swissmedic submission?
A comprehensive package is built on two pillars: Process Transfer and Analytical Method Transfer. The process component details every step from cell expansion and transfection to purification, including all equipment and raw material specifications. The analytical component transfers the qualified or validated assays needed to assess vector identity, purity, potency, and quantity, ensuring consistent product characterization between sites.
How does early-stage capsid selection impact later-stage tech transfer and CMC for AAV therapies?
The choice of AAV capsid profoundly influences the entire manufacturing and analytical control strategy. Different serotypes, such as AAV8 for liver-directed therapies or AAV2 for airway targets, exhibit unique production yields and purification profiles. This selection dictates the specific CQAs that must be monitored and controlled, forming the scientific basis of the tech transfer protocol submitted to regulatory bodies.
For a biotech based in Switzerland, what is the advantage of a CRO with experience across multiple regulatory jurisdictions like the FDA and EMA?
A CRO with multi-jurisdictional experience provides a harmonized approach aligned with ICH guidelines. This ensures that the data package and tech transfer documentation generated for a Swissmedic ATMP submission are structured in a way that can be efficiently leveraged for subsequent submissions to the FDA or EMA, reducing redundant work and accelerating global program timelines.
Aligning AAV Manufacturing and Analytics for Regulatory Success
Transferring manufacturing processes for AAV vectors is a complex scientific undertaking. It requires deep institutional knowledge of the specific vector serotype and its intended clinical application, extending beyond a simple exchange of standard operating procedures. A successful transfer, especially for ATMP submissions to agencies like Swissmedic, hinges on demonstrating process consistency and product comparability between the sending and receiving units.
Our approach is centered on scientific continuity and extensive technical experience. This is particularly valuable for programs transitioning from academic or early discovery phases into a GxP-compliant manufacturing environment.
“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption… Franklin Biolabs serves as a key scientific collaborator for our AAV-vector based gene therapy candidate development, and we hope to continue the partnership for years to come.”
– Biotech Partner
Technical Considerations for AAV Process Transfer
A robust tech transfer protocol for an AAV program must anticipate and mitigate risks associated with scalability and analytical variability. This involves a detailed assessment of the entire production train.
-
Upstream Process: Parameters for adherent or suspension cell culture, including media composition, cell density at transfection, and plasmid ratios, must be precisely defined and replicated.
-
Downstream Process: The purification strategy, often involving chromatography and filtration steps, must be adapted to the equipment and scale at the receiving site while maintaining the vector’s purity profile and full-to-empty capsid ratio.
-
Analytical Comparability: The suite of analytical methods used to release the vector must be formally transferred. This includes assays for vector genome titer, capsid titer, purity, identity, and a phase-appropriate potency assay.
The scientific rationale for these process parameters is informed by a deep understanding of AAV biology. For instance, insights into the differential transduction efficiencies of capsids like AAV3B versus AAV8 in hepatic tissue (PMID: 26412589) or the performance of AAV2/8 in airway epithelium (PMID: 22937069) directly shape the target product profile and the analytical methods chosen to confirm it.
This level of detail ensures the process established at the receiving site is fundamentally equivalent, providing Swissmedic and other global regulators with a high degree of confidence in the consistency of the ATMP. This detailed work supports our ability to help sponsors achieve their IND goals within an 18-24 month timeline, a track record established by our core scientific team prior to the formal 2024 launch of Franklin Biolabs.
Internal Link to Parent Hub: Vector | CMC | Analytics Services
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.